Cue Biopharma (CUE) Insider buying
3 open-market purchases of CUE by Cue Biopharma's executives and directors since August 2023, worth $50,492 in total, from SEC Form 4 filings.
Summary
The most recent: Daniel R Passeri bought $30,900 on December 16, 2024.
The biggest buyer over the period is Daniel R Passeri: 2 purchases, $39,480.
By year
| Year | Purchases | Value |
|---|---|---|
| 2024 | 1 | $30,900 |
| 2023 | 2 | $19,592 |
Biggest buyers
| Insider | Buys | Value |
|---|---|---|
| Daniel R Passeri | 2 | $39,480 |
| Anish Suri | 1 | $11,012 |
Every purchase
Newest first. From SEC Form 4 filings. Insider buying across the market.
Questions about Cue Biopharma
Are Cue Biopharma insiders buying the stock?
3 open-market purchases of CUE by Cue Biopharma's executives and directors since August 2023, worth $50,492 in total, from SEC Form 4 filings. The most recent: Daniel R Passeri bought $30,900 on December 16, 2024.
What counts as insider buying here?
Open-market purchases (Form 4 code P) by officers and directors. Option exercises, grants and purchases by 10% owners are left out.
From Cue Biopharma's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.